Please login to the form below

Not currently logged in
Email:
Password:

Sanofi Pasteur to launch paediatric vaccine in Japan

Sanofi Pasteur, the vaccines division of sanofi-aventis Group, is the first international company to enter the Japanese paediatric vaccine market with its ActHIB

Sanofi Pasteur, the vaccines division of sanofi-aventis Group, is the first international company to enter the Japanese paediatric vaccine market with its ActHIB (Haemophilus influenzae type b) vaccine, which is marketed in Japan by Daiichi-Sankyo.

Hib is transmitted between people through coughing or sneezing. The disease can be carried, with the carrier showing no symptoms but transmitting the disease to others. The risk is highest in children aged between six months and two years.

Hib vaccines became widely available in the 1990s and by 2006 children were immunised in over 120 countries worldwide. The disease affects about 500 children in Japan each year. Of these around 25 will die and a further 100 will suffer from serious conditions such as meningitis and pneumonia as a consequence of Hib infection.

"Sanofi Pasteur is proud to help protect Japanese children against bacterial meningitis and improve public health in the country," said Wayne Pisano president and CEO of Sanofi Pasteur.

"Being the first to enter the Japanese paediatric vaccine market is an achievement that underlines Sanofi Pasteur's strength and commitment to provide the highest quality innovative vaccines."

The ActHIB vaccine will be available in Japan from December 2008.

11th November 2008

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Mednet Group

Communique Small consultancy of the year 2020. With diversity and inclusion at our core, Mednet Group consists of Attigo CIC...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....